NICE Guidance 100 Oxaliplatin and capecitabine - adjuvant
treatment of colorectal cancer
The above NICE appraisal has been considered by NHS Quality
Improvement Scotland through its revised procedure of processing of
NICE appraisals
Web Reference for Guidance and Related Documents:
http://www.nice.org.uk/TA100
NHSScotland should note that:
- No important differences were identified for these NICE
appraisals, and NHS Quality Improvement Scotland advises that they
are as valid for Scotland as for England and Wales.
- NHSScotland should take account of the NICE appraisals and this
NHS Quality Improvement Scotland email in its planning, funding and
provision of services to ensure that recommended drugs or
treatments are made available to meet clinical need.
- NHS Quality Improvement Scotland advice represents the
evidence-based view of NHS Quality Improvement Scotland.
- This advice does not override or replace the individual
responsibility of health professionals to make appropriate
decisions in the circumstances of their individual patients, in
consultation with the patient and/or guardian or carer.
- No other publications on the NICE appraisals will be issued by
NHS Quality Improvement Scotland.
- A copy of the NICE appraisals are attached for your
information. It includes a section on "implications for the NHS"
which you may find helpful in assessing the likely impact of the
health technology locally. Additionally, an easy to read summary of
the guidance, called 'understanding NICE guidance" is published on
the NICE website to provide information for patients and the
public.
- Whilst this email alert is distributed widely in NHSScotland, I
would appreciate if Medical Directors could forward this email to
relevant health professionals in their Board.
- Hard copies of the NICE appraisals are available from NHS
Quality Improvement Scotland (contact Shonagh Buchanan, tel 0141
225 6993 or email shonagh.buchanan@nhshealthquality.org)
Published Date: 28 June 2006
